Last week marked TMC’s first Board meeting since our new CEO, Simon Estcourt succeeded Julie Matthews and, more recently, we welcomed Joe Lopez as CFO.
Simon and Joe join Carol Woodward (COO) and Stewart Sharpe (CCO), completing our C-level team.
Simon commented, “with Joe’s appointment, we are strengthening our leadership team and I’m honoured to be heading up such a reputable and well-established clinical research organisation into the next exciting phase of our Company’s development. The role of specialist CRO’s, like TMC, is more crucial than ever and the work we do is of the utmost importance, as we strive to develop innovative treatments that will improve the quality of life for individuals worldwide.”
Pictured left to right: Joe Lopez, Stefan Gunn, Dewi Hughes, Carol Woodward, Julie Matthews, Thomas Engelen, Stewart Sharpe, Simon Escourt.
If you’d like to learn more about our Company’s full-service CRO capabilities please contact us at: info@tmcpharma.com.